Efficacies of atovaquone, Pentamidine (cas 100-33-4), and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases

Add time:07/21/2019    Source:sciencedirect.com

BackgroundPneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in patients on steroid therapy for connective tissue diseases. The standard agent for primary PCP prophylaxis is trimethoprim/sulfamethoxazole (TMP-SMX), although this agent can cause common adverse reactions, including myelosuppression and renal toxicity, that result in cessation. Aerosolized pentamidine and oral atovaquone are alternatives for PCP prophylaxis. The efficacies of atovaquone, pentamidine, and TMP-SMX to prevent PCP in patients with connective tissue diseases have never been compared.

We also recommend Trading Suppliers and Manufacturers of Pentamidine (cas 100-33-4). Pls Click Website Link as below: cas 100-33-4 suppliers

Prev:inPentasomes: An innovative nose-to-brain Pentamidine (cas 100-33-4) delivery blunts MPTP parkinsonism in mice
Next:The antitrypanosomal diarylamidines, diminazene and Pentamidine (cas 100-33-4), show anthelmintic activity against Haemonchus contortus in vitro)